Surmodics traded at $38.04 this Friday August 12th, increasing $0.85 or 2.29 percent since the previous trading session. Looking back, over the last four weeks, Surmodics gained 10.45 percent. Over the last 12 months, its price fell by 28.36 percent. Looking ahead, we forecast Surmodics to be priced at 32.86 by the end of this quarter and at 30.21 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
38.04
Daily Change
2.29%
Yearly
-28.36%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abbott 111.48 0.99 0.90% -9.41%
Align Technology 289.00 1.62 0.56% -58.19%
Anika Therapeutics 22.38 0.64 2.94% -46.51%
Arrowhead Research 47.29 1.66 3.64% -21.86%
Baxter International 60.46 0.49 0.82% -18.91%
BioScrip 34.77 0.60 1.76% 63.70%
Boston Scientific 42.33 0.57 1.36% -4.51%
Artivion Inc 22.72 0.96 4.41% -9.63%
EDAP TMS 7.49 0.17 2.32% 33.75%
Edwards Lifesciences 104.80 0.88 0.85% -7.38%
Haemonetics 75.20 2.13 2.92% 23.00%
Heron Therapeutics 5.30 0.43 8.83% -52.04%
J&J 165.30 -1.84 -1.10% -6.21%
Mesa Laboratories 196.14 5.50 2.89% -29.62%
Merit Medical Systems 62.98 0.98 1.58% -4.58%
Nektar Therapeutics 5.14 0.19 3.84% -64.03%
Surmodics 38.04 0.85 2.29% -28.36%
Stryker 223.12 5.11 2.34% -15.21%
Trinity Biotech 1.41 0.03 2.17% -35.62%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Surmodics
Surmodics, Inc. is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.